| Literature DB >> 24333781 |
Claus Dieter Schuh1, Sandra Pierre1, Andreas Weigert2, Benjamin Weichand2, Kai Altenrath1, Yannick Schreiber1, Nerea Ferreiros1, Dong Dong Zhang1, Jing Suo1, Elsa-Marie Treutlein1, Marina Henke1, Hana Kunkel3, Manuel Grez3, Rolf Nüsing1, Bernhard Brüne2, Gerd Geisslinger1, Klaus Scholich4.
Abstract
Prostacyclin is an important mediator of peripheral pain sensation. Here, we investigated its potential participation in mediating neuropathic pain and found that prostacyclin receptor (IP) knockout mice exhibited markedly decreased pain behavior. Application of an IP antagonist to the injury site or selective IP deficiency in myeloid cells mimicked the antinociceptive effect observed in IP knockout mice. At the site of nerve injury, IP was expressed in interleukin (IL) 1β-containing resident macrophages, which were less common in IP knockout mice. Local administration of the IP agonist cicaprost inhibited macrophage migration in vitro and promoted accumulation of IP- and IL1β-expressing cells as well as an increase of IL1β concentrations at the application site in vivo. Fittingly, the IL1-receptor antagonist anakinra (IL-1ra) decreased neuropathic pain behavior in wild-type mice but not in IP knockout mice. Finally, continuous, but not single administration, of the cyclooxygenase inhibitor meloxicam early after nerve injury decreased pain behavior and the number of resident macrophages. Thus, early synthesis of prostacyclin at the site of injury causes accumulation of IL1β-expressing macrophages as a key step in neuropathic pain after traumatic injury.Entities:
Keywords: Cyclooxygenase; Interleukin 1β; Macrophages; Neuropathic pain; Prostacyclin
Mesh:
Substances:
Year: 2013 PMID: 24333781 DOI: 10.1016/j.pain.2013.12.006
Source DB: PubMed Journal: Pain ISSN: 0304-3959 Impact factor: 6.961